Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 21Endocrine 21Thoracic 2Sarcoma 2NET 2Gastrointestinal 2CNS 2Plasma cell 1Other hematologic neoplasm 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 1363Lung Neoplasms 697Small Cell Lung Carcinoma 202Neoplasms 151Neoplasm Metastasis 130Breast Neoplasms 116Melanoma 99Colorectal Neoplasms 84Adenocarcinoma of Lung 84Ovarian Neoplasms 78Pancreatic Neoplasms 72Carcinoma, Renal Cell 69Head and Neck Neoplasms 66Mesothelioma 58Prostatic Neoplasms 53Urinary Bladder Neoplasms 52Mesothelioma, Malignant 51Stomach Neoplasms 47Triple Negative Breast Neoplasms 45Carcinoma 45Esophageal Neoplasms 43Brain Neoplasms 42Squamous Cell Carcinoma of Head and Neck 41Colonic Neoplasms 35Sarcoma 34Adenocarcinoma, Bronchiolo-Alveolar 33Recurrence 32Adenocarcinoma 31Uterine Cervical Neoplasms 30Parkinson Disease 4, Autosomal Dominant Lewy Body 29

Interventions

tislelizumab 1surufatinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Thyroid Carcinoma, Anaplastic × Thoracic × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Completed
319 enrolled 41 charts
BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡